HK1232242A1 - 用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物 - Google Patents
用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物Info
- Publication number
- HK1232242A1 HK1232242A1 HK17106011.3A HK17106011A HK1232242A1 HK 1232242 A1 HK1232242 A1 HK 1232242A1 HK 17106011 A HK17106011 A HK 17106011A HK 1232242 A1 HK1232242 A1 HK 1232242A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- subunit
- pharmaceutical composition
- therapeutic agent
- based therapeutic
- cancer targeting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6445—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462019925P | 2014-07-02 | 2014-07-02 | |
| US14/752,999 US9814759B2 (en) | 2014-07-02 | 2015-06-28 | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
| PCT/CN2015/083041 WO2016000616A1 (en) | 2014-07-02 | 2015-07-01 | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1232242A1 true HK1232242A1 (zh) | 2018-01-05 |
Family
ID=55016241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK17106011.3A HK1232242A1 (zh) | 2014-07-02 | 2017-06-16 | 用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9814759B2 (zh) |
| EP (1) | EP3164412A4 (zh) |
| KR (1) | KR20170026485A (zh) |
| CN (1) | CN106715468A (zh) |
| AR (1) | AR101101A1 (zh) |
| AU (1) | AU2015283394B2 (zh) |
| CA (1) | CA2953173A1 (zh) |
| HK (1) | HK1232242A1 (zh) |
| SG (2) | SG10201807554QA (zh) |
| TW (1) | TWI633118B (zh) |
| UY (1) | UY36202A (zh) |
| WO (1) | WO2016000616A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20237496B (en) | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US11560384B2 (en) | 2017-05-04 | 2023-01-24 | University Of Utah Research Foundation | Benzonorbornadiene derivatives and reactions thereof |
| US10946099B2 (en) * | 2017-06-27 | 2021-03-16 | Vision Global Holdings Limited | Compositions for photodynamic therapy and fluorescence diagnosis of cancers and other diseases |
| CN110256571A (zh) * | 2018-11-30 | 2019-09-20 | 莱尔芙高新技术(上海)有限公司 | 重组人白蛋白-血红蛋白β亚基融合蛋白 |
| US10752672B1 (en) * | 2019-02-01 | 2020-08-25 | Cheer Global Limited | Recombinant hemoglobins and methods of preparation and use thereof |
| WO2020241340A1 (ja) * | 2019-05-24 | 2020-12-03 | 株式会社糖鎖工学研究所 | 新規な人工タンパク質触媒 |
| EP3999529A4 (en) * | 2019-07-19 | 2023-07-12 | Cheer Global Limited | HEMOGLOBIN-BASED THERAPEUTIC AGENT |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600531A (en) | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
| US5449759A (en) | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
| US5599907A (en) | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
| US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
| US6172039B1 (en) * | 1990-04-16 | 2001-01-09 | Apex Bioscience, Inc. | Expression of recombinant hemoglobin and hemoglobin variants in yeast |
| EP0611306B1 (en) * | 1991-11-08 | 1998-07-08 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
| CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
| WO2006113540A2 (en) * | 2005-04-14 | 2006-10-26 | Duke University | Use of ntrosylated hemoglobin |
| US7989593B1 (en) | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US8742073B2 (en) | 2010-05-27 | 2014-06-03 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US8048856B1 (en) | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
| US7932356B1 (en) | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
| US8084581B1 (en) | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
| US20130052232A1 (en) | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| US20140106004A1 (en) | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| MA38571B1 (fr) * | 2013-05-13 | 2018-10-31 | Vision Global Holdings Ltd | Composition pharmaceutique comprenant un agent thérapeutique à base d'hémoglobine modifiée pour un traitement de ciblage du cancer et imagerie diagnostique |
-
2015
- 2015-06-28 US US14/752,999 patent/US9814759B2/en active Active
- 2015-06-30 TW TW104121109A patent/TWI633118B/zh not_active IP Right Cessation
- 2015-07-01 WO PCT/CN2015/083041 patent/WO2016000616A1/en active Application Filing
- 2015-07-01 CN CN201580047951.7A patent/CN106715468A/zh active Pending
- 2015-07-01 KR KR1020177001611A patent/KR20170026485A/ko unknown
- 2015-07-01 SG SG10201807554QA patent/SG10201807554QA/en unknown
- 2015-07-01 EP EP15815035.9A patent/EP3164412A4/en not_active Withdrawn
- 2015-07-01 CA CA2953173A patent/CA2953173A1/en not_active Abandoned
- 2015-07-01 AU AU2015283394A patent/AU2015283394B2/en not_active Ceased
- 2015-07-01 SG SG11201610947UA patent/SG11201610947UA/en unknown
- 2015-07-02 AR ARP150102131A patent/AR101101A1/es unknown
- 2015-07-02 UY UY0001036202A patent/UY36202A/es not_active Application Discontinuation
-
2017
- 2017-06-16 HK HK17106011.3A patent/HK1232242A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201807554QA (en) | 2018-10-30 |
| US9814759B2 (en) | 2017-11-14 |
| TWI633118B (zh) | 2018-08-21 |
| CN106715468A (zh) | 2017-05-24 |
| AU2015283394B2 (en) | 2019-04-11 |
| CA2953173A1 (en) | 2016-01-07 |
| UY36202A (es) | 2016-01-29 |
| AU2015283394A1 (en) | 2017-01-19 |
| KR20170026485A (ko) | 2017-03-08 |
| US20160000864A1 (en) | 2016-01-07 |
| EP3164412A4 (en) | 2018-03-28 |
| AR101101A1 (es) | 2016-11-23 |
| EP3164412A1 (en) | 2017-05-10 |
| SG11201610947UA (en) | 2017-01-27 |
| WO2016000616A1 (en) | 2016-01-07 |
| TW201613960A (en) | 2016-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE054316T2 (hu) | Gyógyászati készítmény rák kezelésére | |
| IL260383B (en) | Low dose medication | |
| IL253712A0 (en) | Mysterlein derivatives for coupling and healing | |
| HK1232242A1 (zh) | 用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物 | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| IL258854A (en) | Preparations containing cannabidiol and secondary medicinal agents for cancer treatment | |
| IL261824A (en) | Pharmaceutical combinations for cancer treatment | |
| GB201411465D0 (en) | Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer | |
| HK1223037A1 (zh) | 用於癌症靶向治療和診斷成像的包含基於修飾的血紅蛋白的治療劑的藥物組合物 | |
| HUE055433T2 (hu) | Kombinált készítmény rák kezelésére | |
| IL251349B (en) | Routing of melanocytes for the transfer of medical or diagnostic substances using nano-cage proteins | |
| ZA201802452B (en) | New therapeutic strategies against blood cancer | |
| HK1250662A1 (zh) | 用於治療癌症的免疫原性融合蛋白 | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| EP3375443A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES | |
| IL270140B (en) | A therapeutic agent for blood cancer | |
| PT3120852T (pt) | Agente preventivo e/ou terapêutico para doenças imunitárias | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| KR20180085033A (ko) | 피부 질환 치료용 약학적 제형 및 이의 제조 방법 | |
| HK1259026A1 (zh) | 用於治療癌症的抗趨除劑的局部遞送 | |
| SG11201801083UA (en) | Tumor therapeutic agent | |
| AP2015008848A0 (en) | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |